



**FOR IMMEDIATE RELEASE**

**TSX: BMR**

**BRADMER ANNOUNCES DR. PHIL GOLD TO JOIN BOARD OF DIRECTORS**

**Toronto, Ontario – August 15, 2007** – Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Phil Gold, C.C., O.Q., M.D., Ph.D., has agreed to join the Company's Board of Directors effective immediately. Dr. Gold is a pioneer in the study of oncology and physiology with over 40 years of experience in clinical and academic settings. His early research led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer.

"Dr. Gold's extensive experience in the study and management of cancer will be of great benefit to our Board of Directors and the senior management team at Bradmer," said Mark C. Rogers, M.D., Executive Chairman of Bradmer. "As one of the most prominent clinical investigators in Montreal, Dr. Gold has demonstrated a commitment, over the course of his career, to help patients through direct patient care as well as working with the pharmaceutical industry in developing innovative new therapies. The addition of Dr. Gold is an example of Bradmer's ability, based on our novel Neuradiab therapy, to attract thought leaders in the oncology space."

Dr. Gold is currently the Executive Director of the Clinical Research Centre of the McGill University Health Centre. He has also served as Chairman of the Department of Medicine at McGill and Physician-in-Chief at the Montreal General Hospital. Dr. Gold has been elected to numerous professional organizations including the American Society for Clinical Investigation, the Association of American Physicians, and Mastership in the American College of Physicians. He has been the recipient of a number of prestigious awards including his appointment as a Companion of the Order of Canada and the Robert Taylor Gold Medal from the National Cancer Institute of Canada. Dr. Gold is a graduate of McGill University where he completed his B.Sc. and M.Sc. in physiology and where he later completed his MDCM and Ph.D. In 2006, the Phil Gold Chair in Medicine was inaugurated at McGill University. Dr. Gold will be replacing Mr. Doug Janzen, President and Chief Business Officer of Cardiome Pharma Corp. (NASDAQ: CRME, TSX: COM) on the Board of Bradmer.

**About Bradmer Pharmaceuticals Inc. ([www.bradmerpharma.com](http://www.bradmerpharma.com))**

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US\$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

*Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.*

*Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*

**For further information contact:**

Bradmer Pharmaceuticals Inc.  
Mr. Brian Brohman  
Chief Business and Financial Officer  
Phone: (416) 361-6058 (Ext. 804)  
E-mail: [bbrohman@bradmerpharma.com](mailto:bbrohman@bradmerpharma.com)  
Internet: [www.bradmerpharma.com](http://www.bradmerpharma.com)

Investor Relations  
Ross Marshall  
The Equicom Group Inc.  
Phone: (416) 815-0700 (Ext. 238)  
Fax: (416) 815-0080  
E-mail: [rmarshall@equicomgroup.com](mailto:rmarshall@equicomgroup.com)